Selux Diagnostics, Inc. news

Selux Diagnostics Announces Additional $50 Million in Series C Funding

Selux Diagnostics, Inc., which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, today announced it has raised $50 million in Series C financing to support the U.S. commercial launch of its Next-Generation P

Feb. 28, 2022

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

Nov. 16, 2021

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

Oct. 19, 2021

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

Sep. 28, 2021

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation `Phenotyping` (NGP) Platform for Positive Blood Culture and Sterile Body Fluid samples

Sep. 28, 2021